Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
After a median follow-up of 13 months, four of the five patients had ongoing complete remission.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
An inside look at five research developments that have the potential to transform the treatment of cancer
The CAR-T therapy led to complete remission in 60% of people with relapsed or refractory follicular lymphoma.
Study finds that ide-cel produces remissions in almost 75% of patients with multiple myeloma who had relapsed after previous treatments.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
Scientists at Dana-Farber Cancer Institute have created molecular ON-OFF switches to regulate the activity of CAR T cells.
Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.
Combining machine learning with cell engineering, scientists can design ‘living medicines’ that precisely target tumors
The gene-editing tool can alter the DNA of human cells like a precise pair of scissors.
Tecartus led to durable remission in a majority of participants in a Phase II study.
KTE-X19 led to durable remission in a majority of study participants.
“Ultimately, we want to cure the many forms of cancer, but one strategy is not going to work for all, thus the need for innovation.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.